- Home
- » Tags
- » Onartuzumab
Top View
- FOLFOX Alone Or Combined with Rilotumumab Or Panitumumab As
- Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer
- ESMO 2012 Ficlatuzumab PKPD Poster
- Evolution of Escherichia Coli Expression System in Producing Antibody Recombinant Fragments
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
- Snapshot: Breast Cancer Kornelia Polyak and Otto Metzger Filho Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215 USA
- Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma
- An Overview of the Current Status of Engineered Therapeutic Monoclonal Antibodies
- The Example of Lung Cancer Perrine Créquit1,2†, Ludovic Trinquart1,2,3,4*†, Amélie Yavchitz1,2,3 and Philippe Ravaud1,2,3,4,5
- Supplementary Appendix
- Combining Onartuzumab with Erlotinib Inhibits Growth of Non
- Exane BNP Paribas 14Th Healthcare Conference May 10, 2012
- Prevalence of Androgen Receptor Positivity in Triple Negative Breast
- Monoclonal Antibodies in Non-Small-Cell Lung Cancer
- A Randomized Phase II Study of FOLFOX with Or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction
- Targeted Therapy for NSCLC–A Double-Edged Sword?
- Review Recent Updates of Therapeutic Strategy of Esophagogastric
- Supplementary Tables and Figures Section 1. Distribution of CDR-H3
- Patterns in Target-Directed Breast Cancer Research
- Bone Metastases from Prostate Cancer
- Novel Systemic Therapies for Advanced Gastric Cancer
- Pathogenetic Features and Current Management of Glioblastoma
- Non-Small Cell Lung Cancer – Germany Drug Forecast and Market Analysis to 2022
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
- Listes De DCI Proposées N'implique Aucune Recommandation En Vue De L'utilisation De La Substance Correspondante En Médecine Ou En Pharmacie
- 89Zr-Onartuzumab PET Imaging of C-MET Receptor Dynamics
- Anti-Alphavbeta3 Monoclonal Antibody EMD 525797 (CUI C2830088) Add to Cart
- Orphan Drug Designations and Approvals List As of 12‐01‐2014
- Advances in Targeted Therapy for Esophageal Cancer
- Onartuzumab for Metastatic Met Positive Non-Small Cell Lung Cancer
- Current Advances of Targeting HGF/C-Met Pathway in Gastric Cancer
- Targeted Therapy for Advanced Gastric Cancer: a Review of Current Status and Future Prospects
- (INN) for Biological and Biotechnological Substances
- First-Line Onartuzumab Plus Erlotinib Treatment for Patients with MET
- Second-Line Combination Therapies in Nonsmall Cell Lung Cancer Without Known Driver Mutations
- A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy
- Novel Therapies for Advanced Gastric Cancer
- Metastatic Non-Small Cell Lung Cancer: ESMO Clinical Practice Guidelines
- Algorithm for the Treatment of Advanced Or Metastatic Squamous Non-Small-Cell Lung Cancer: an Evidence-Based Overview
- Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2
- Case 2 – Lack of Response to Trastuzumab in a Patient with Metastatic Gastric Cancer Progressing After Extended Response to MET Inhibitor Therapy
- Necitumumab (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022
- Low Protein Expression of MET in ER-Positive and HER2-Positive Breast Cancer
- Targeted Therapy in Esophageal Cancer
- A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases
- Comprehensive Review of Targeted Therapy for Colorectal Cancer
- Effect of Fluorouracil, Leucovorin, and Oxaliplatin with Or Without
- The Potential Roles of Hepatocyte Growth Factor (HGF)-MET Pathway Inhibitors in Cancer Treatment
- Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
- Cmet Axis in Cancer Therapy
- New Target Therapies in Advanced Non-Small Cell Lung Cancer: a Review of the Literature and Future Perspectives